Evidence map›Paper›PMID 42293468›Full record

ArticleRadiology case reports2026

Hepatocellular carcinoma in a child with hereditary tyrosinemia type I despite early NTBC therapy: When should we suspect it?

Karima Larbi Ouassou, Rachid Abilkassem

Abstract readCase Reports
In one paragraph

Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Karima Larbi OuassouDepartment of Pediatrics, Military Hospital of Instruction Mohammed V, Rabat, Morocco.
Rachid AbilkassemDepartment of Pediatrics, Military Hospital of Instruction Mohammed V, Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosinemia is one of the rare metabolic diseases in children. Treatment with NTBC has significantly reduced the risk of cirrhosis and therefore of neoplastic complications, including hepatocellular carcinoma, especially if treatment is started early. Close monitoring of children with this disease is necessary and must include thorough clinical, biological, and radiological investigations in the event of any suspicion of malignant complications. Liver transplantation has been the subject of much controversy in the curative treatment of the disease, as well as its major complication, hepatocellular carcinoma.

Indexed as

Hepatocellular carcinoma liverInfantMRIPediatricsTransplantationTyrosinémia

Identifiers

PMID42293468
PMCPMC13254964

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.